Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash from Financing Activities (2020 - 2025)

Roivant Sciences' Cash from Financing Activities history spans 6 years, with the latest figure at $328.2 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 131.48% year-over-year to $328.2 million; the TTM value through Dec 2025 reached -$839.6 million, up 38.28%, while the annual FY2025 figure was -$1.2 billion, 390.87% down from the prior year.
  • Cash from Financing Activities reached $328.2 million in Q4 2025 per ROIV's latest filing, up from $62.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $452.0 million in Q4 2023 to a low of -$1.0 billion in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $6.8 million, with a median of $62.6 million recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: surged 2931.66% in 2023, then crashed 8935.31% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $305.7 million in 2021, then dropped by 5.43% to $289.1 million in 2022, then surged by 56.33% to $452.0 million in 2023, then plummeted by 330.68% to -$1.0 billion in 2024, then surged by 131.48% to $328.2 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Cash from Financing Activities are $328.2 million (Q4 2025), $62.6 million (Q3 2025), and -$187.8 million (Q2 2025).